A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia

Of the 3,100 children diagnosed with acute lymphoblastic leukemia (ALL) in the U.S. each year [1], approximately 10% will ultimately succumb to their disease [2,3]. Prognosis is far worse for the>3,000 U.S. adults diagnosed annually, with only about 30-40% 5-year overall survival among this cohort [4,5]. Nearly 1 in 10 adults will never even achieve remission, and more than half of those who do will go on to suffer relapse and disease-related mortality [6].

Source: Leukemia Research - November 3, 2018 Category: Hematology Authors: Carol Fries, W. Richard Burack Source Type: research